B

iotech executives appear slightly less concerned about drug pricing than in the recent past, according to a new analysis, but the continued pressure from payers and lawmakers to bring down costs does still weigh on them.

A review of risk factors cited by the 100 largest companies listed in the Nasdaq Biotechnology Index found 84 percent cited worries over pricing pressures, according to the BDO advisory and consulting firm, which examined the most recent crop of annual filings with the US Securities and Exchange Commission.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X